Topiramate is an antiepileptic indicated for epilepsy and preventive treatment of migraine. We supply it to US manufacturers of tablets, sprinkle capsules and extended-release capsules.
Data from PubChem (CID 5284627) and FDA’s substance registry
CAS number
97240-79-4
Molecular formula
C12H21NO8S
Molecular weight
339.4g/mol
FDA UNII
IUPAC name
[(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.02,6]dodecan-6-yl]methyl sulfamate
InChIKey
KJADKKWYZYXHBB-XBWDGYHZSA-N
- Appearance
- White crystalline powder with a bitter taste.
- Solubility
- Most soluble in alkaline solutions at pH 9 to 10. Freely soluble in acetone, chloroform, dimethyl sulfoxide and ethanol.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Degrades with heat and moisture, releasing sulfate and sulfamate. Compare the limits for both, and the storage conditions, between sources.
On the US market
- Reference product
- TopamaxNDA 020505
- Approved ANDAs
- 33 with a marketed product
- Approved forms and strengths
- Extended-release capsule 25 mg, 50 mg, 100 mg, 150 mg, 200 mg
- Tablet 25 mg, 50 mg, 100 mg, 200 mg
- Capsule 15 mg, 25 mg, 50 mg
- Oral solution 25 mg/mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com
Sertraline Hydrochloride
Selective serotonin reuptake inhibitor (SSRI)
CAS 79559-97-0Escitalopram Oxalate
Selective serotonin reuptake inhibitor (SSRI)
CAS 219861-08-2Duloxetine Hydrochloride
Serotonin-norepinephrine reuptake inhibitor (SNRI)
CAS 136434-34-9Bupropion Hydrochloride
Norepinephrine-dopamine reuptake inhibitor
CAS 31677-93-7